FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

The phase III RV144 HIV-1 vaccine trial estimated vaccine efficacy (VE) to be 31.2%. This trial demonstrated that the presence of HIV-1–specific IgG-binding Abs to envelope (Env) V1V2 inversely correlated with infection risk, while the presence of Env-specific plasma IgA Abs directly correlated with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Li, Shuying S., Gilbert, Peter B., Tomaras, Georgia D., Kijak, Gustavo, Ferrari, Guido, Thomas, Rasmi, Pyo, Chul-Woo, Zolla-Pazner, Susan, Montefiori, David, Liao, Hua-Xin, Nabel, Gary, Pinter, Abraham, Evans, David T., Gottardo, Raphael, Dai, James Y., Janes, Holly, Morris, Daryl, Fong, Youyi, Edlefsen, Paul T., Li, Fusheng, Frahm, Nicole, Alpert, Michael D., Prentice, Heather, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Robb, Merlin L., O’Connell, Robert J., Haynes, Barton F., Michael, Nelson L., Kim, Jerome H., McElrath, M. Juliana, Geraghty, Daniel E.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2014
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151214/
https://ncbi.nlm.nih.gov/pubmed/25105367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI75539
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares